Semantic/JJ
Modeling/JJ
for/IN
SNPs/NNS
Associated/VBN
with/IN
Ethnic/JJ
Disparities/NNS
in/IN
HapMap/NN
Samples/NNS
./.
====================
Single-nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
have/VBP
been/VBN
emerging/VBG
out/RP
of/IN
the/DT
efforts/NNS
to/TO
research/NN
human/JJ
diseases/NNS
and/CC
ethnic/JJ
disparities/NNS
./.
====================
A/DT
semantic/JJ
network/NN
is/VBZ
needed/VBN
for/IN
in-depth/JJ
understanding/NN
of/IN
the/DT
impacts/NNS
of/IN
SNPs/NNS
,/,
because/IN
phenotypes/NNS
are/VBP
modulated/VBN
by/IN
complex/NN
networks/NNS
,/,
including/VBG
biochemical/JJ
and/CC
physiological/JJ
pathways/NNS
./.
====================
We/PRP
identified/VBD
ethnicity-specific/JJ
SNPs/NNS
by/IN
eliminating/VBG
overlapped/VBD
SNPs/NNS
from/IN
HapMap/NN
samples/NNS
,/,
and/CC
the/DT
ethnicity-specific/JJ
SNPs/NNS
were/VBD
mapped/VBN
to/TO
the/DT
UCSC/NN
RefGene/NN
lists/NNS
./.
====================
Ethnicity-specific/JJ
genes/NNS
were/VBD
identified/VBN
as/IN
follows/VBZ
:/:
22/CD
genes/NNS
in/IN
the/DT
USA/NN
(/(
CEU/NN
)/)
individuals/NNS
,/,
25/CD
genes/NNS
in/IN
the/DT
Japanese/JJ
(/(
JPT/NN
)/)
individuals/NNS
,/,
and/CC
332/CD
genes/NNS
in/IN
the/DT
African/JJ
(/(
YRI/NN
)/)
individuals/NNS
./.
====================
To/TO
analyze/VB
the/DT
biologically/RB
functional/JJ
implications/NNS
for/IN
ethnicity-specific/JJ
SNPs/NNS
,/,
we/PRP
focused/VBD
on/IN
constructing/VBG
a/DT
semantic/JJ
network/NN
model/NN
./.
====================
Entities/NNS
for/IN
the/DT
network/NN
represented/VBN
by/IN
``/CD
Gene/NN
,/,
''/NNP
``/CD
Pathway/NN
,/,
''/NNP
``/CD
Disease/NN
,/,
''/NNP
``/CD
Chemical/JJ
,/,
''/NNP
``/CD
Drug/NN
,/,
''/NNP
``/CD
ClinicalTrials/NNS
,/,
''/NNP
``/CD
SNP/NN
,/,
''/NNP
and/CC
relationships/NNS
between/IN
entity-entity/NN
were/VBD
obtained/VBN
through/IN
curation/NN
./.
====================
Our/PRP$
semantic/JJ
modeling/VBG
for/IN
ethnicity-specific/JJ
SNPs/NNS
showed/VBD
interesting/JJ
results/NNS
in/IN
the/DT
three/CD
categories/NNS
,/,
including/VBG
three/CD
diseases/NNS
(/(
``/NNP
AIDS-associated/JJ
nephropathy/RB
,/,
''/NNP
``/NNP
Hypertension/NN
,/,
''/NNP
and/CC
``/FW
Pelvic/JJ
infection/NN
''/NNP
)/)
,/,
one/CD
drug/NN
(/(
``/NNP
Methylphenidate/NNP
''/NNP
)/)
,/,
and/CC
five/CD
pathways/NNS
(/(
``/NNP
Hemostasis/NN
,/,
''/NNP
``/NNP
Systemic/JJ
lupus/NN
erythematosus/NN
,/,
''/NNP
``/NNP
Prostate/JJ
cancer/NN
,/,
''/NNP
``/NNP
Hepatitis/NN
C/NN
virus/NN
,/,
''/NNP
and/CC
``/FW
Rheumatoid/JJ
arthritis/NN
''/RB
)/)
./.
====================
We/PRP
found/VBD
ethnicity-specific/JJ
genes/NNS
using/VBG
the/DT
semantic/JJ
modeling/VBG
,/,
and/CC
the/DT
majority/NN
of/IN
our/PRP$
findings/NNS
was/VBD
consistent/JJ
with/IN
the/DT
previous/JJ
studies/NNS
-/:
that/DT
an/DT
understanding/NN
of/IN
genetic/JJ
variability/NN
explained/VBN
ethnicity-specific/JJ
disparities/NNS
./.
====================
Tremendous/JJ
efforts/NNS
have/VBP
been/VBN
made/VBN
to/TO
identify/VB
ethnicity-specific/JJ
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
in/IN
human/JJ
diseases/NNS
[/(
1/CD
,/,
2/CD
]/)
./.
====================
Dosage/NN
effect/NN
or/CC
disease/NN
susceptibility/NN
is/VBZ
not/RB
equal/JJ
among/IN
ethnic/JJ
groups/NNS
./.
====================
Type/NN
2/CD
diabetes/NNS
prevalence/NN
is/VBZ
12.8/CD
%/NN
,/,
8.4/CD
%/NN
,/,
and/CC
6.6/CD
%/NN
in/IN
non-Hispanic/JJ
blacks/NNS
,/,
in/IN
Mexican-Americans/NNS
,/,
and/CC
in/IN
non-Hispanic/JJ
whites/VBZ
aged/JJ
20/CD
years/NNS
or/CC
older/JJR
[/(
3/CD
]/)
./.
====================
Ethnic/JJ
differences/NNS
were/VBD
causes/VBZ
of/IN
environmental/JJ
exposure/NN
and/CC
experiences/VBZ
with/IN
health/NN
care/JJ
,/,
and/CC
these/DT
ethnic/JJ
disparities/NNS
likely/JJ
influence/VBP
different/JJ
outcomes/NNS
in/IN
people/JJ
with/IN
certain/JJ
diseases/NNS
[/(
4/CD
]/)
./.
====================
Genetic/JJ
differences/NNS
also/RB
can/MD
not/RB
ignore/VB
its/PRP$
important/JJ
role/NN
in/IN
determining/VBG
ethnic/JJ
disparities/NNS
./.
====================
Despite/IN
recent/JJ
advances/NNS
in/IN
the/DT
genetic/JJ
studies/NNS
for/IN
ethnic/JJ
disparities/NNS
,/,
little/JJ
is/VBZ
known/VBN
about/IN
how/WRB
ethnic/JJ
genetic/JJ
differences/NNS
contribute/VBP
to/TO
inter-ethnic/JJ
disparities/NNS
in/IN
disease/NN
risk/NN
or/CC
disease-related/JJ
complex/NN
traits/VBZ
[/(
5/CD
]/)
./.
====================
Recently/RB
,/,
semantic/JJ
modeling/VBG
has/VBZ
gained/VBN
attention/NN
as/IN
a/DT
powerful/JJ
tool/NN
for/IN
organizing/VBG
and/CC
integrating/JJ
biological/JJ
big/NN
data/NNS
[/(
6/CD
]/)
./.
====================
Semantic/JJ
technology/NN
is/VBZ
needed/VBN
to/TO
provide/VB
the/DT
knowledge/NN
to/TO
gain/VB
an/DT
adequate/NN
interpretation/NN
of/IN
integrated/JJ
biological/JJ
systems/NNS
[/(
7/CD
]/)
./.
====================
Recent/JJ
advances/NNS
in/IN
ontology/JJ
development/NN
,/,
like/IN
semantic/JJ
modeling/VBG
,/,
are/VBP
considered/VBN
to/TO
contribute/VB
to/TO
the/DT
next-generation/NN
approach/NN
by/IN
enabling/VBG
the/DT
researcher/JJ
to/TO
actually/RB
ask/VB
scientific/JJ
questions/NNS
instead/RB
of/IN
constructing/VBG
complicated/VBN
databases/NNS
for/IN
scientific/JJ
questions/NNS
and/CC
answers/NNS
[/(
8/CD
]/)
./.
====================
This/DT
combination/NN
of/IN
data/NNS
integration/NN
and/CC
visualization/NN
could/MD
provide/VB
important/JJ
insights/NNS
into/IN
heterogeneous/JJ
data/NNS
on/IN
millions/NNS
of/IN
genes/NNS
,/,
chemical/JJ
compounds/NNS
,/,
diseases/NNS
,/,
and/CC
pathways/NNS
[/(
9/CD
,/,
10/CD
]/)
./.
====================
To/TO
model/VB
a/DT
semantic/JJ
network/NN
,/,
the/DT
BioXM/NN
software/RB
is/VBZ
a/DT
customizable/JJ
knowledge/NN
management/JJ
program/NN
for/IN
large/JJ
scientific/JJ
data/NNS
,/,
and/CC
the/DT
latest/JJ
solution/NN
is/VBZ
designed/VBN
to/TO
provide/VB
meaningful/JJ
interactions/NNS
through/IN
graphical/JJ
browsing/VBG
[/(
11/CD
]/)
./.
====================
Through/IN
an/DT
advanced/JJ
query/RB
builder/NN
,/,
the/DT
knowledge/NN
consisting/VBG
of/IN
many/JJ
different/JJ
and/CC
connected/VBD
queries/NNS
is/VBZ
flexibly/RB
examined/VBN
./.
====================
In/IN
this/DT
way/NN
,/,
models/NNS
for/IN
a/DT
research/NN
project/VB
can/MD
be/VB
constructed/VBN
and/CC
extended/VBD
effectively/RB
./.
====================
Many/JJ
data/NNS
modeling/VBG
studies/NNS
and/CC
software/JJ
developments/NNS
have/VBP
been/VBN
advanced/JJ
,/,
but/CC
there/EX
are/VBP
relatively/RB
few/JJ
studies/NNS
using/VBG
semantic/JJ
modeling/VBG
for/IN
ethnicity-specific/JJ
SNPs/NNS
./.
====================
To/TO
evaluate/VB
the/DT
ethnic/JJ
disparities/VBZ
,/,
in/IN
the/DT
current/JJ
study/NN
,/,
we/PRP
identified/VBD
ethnicity-specific/JJ
SNPs/NNS
for/IN
three/CD
populations/NNS
,/,
including/VBG
North/NN
Americans/NNS
with/IN
European/JJ
ancestry/NN
(/(
CEU/NN
)/)
,/,
Japanese/JJ
from/IN
Tokyo/JJ
(/(
JPT/NN
)/)
,/,
and/CC
Yorubans/NNS
from/IN
Ibadan/JJ
(/(
YRI/NN
)/)
from/IN
HapMap/NN
,/,
and/CC
constructed/VBD
a/DT
semantic/JJ
model/NN
for/IN
ethnicity-specific/JJ
SNPs/NNS
./.
====================
We/PRP
expect/VBP
that/DT
semantic/JJ
model-based/VBN
research/NN
will/MD
provide/VB
valuable/JJ
information/NN
on/IN
ethnicity-specific/JJ
gene-based/VBN
SNPs/NNS
and/CC
strongly/RB
affect/VB
useful/JJ
knowledge/NN
in/IN
ethnic/JJ
disparities/NNS
./.
====================
Study/NN
subjects/NNS
====================
We/PRP
downloaded/VBD
the/DT
SNPs/NNS
data/NNS
from/IN
Haplotype/NN
Map/NN
(/(
HapMap/NN
)/)
phase/NN
3/CD
(/(
http/NN
:/:
//www.hapmap.org/JJ
)/)
for/IN
CEU/NN
(/(
Utah/NNP
residents/NNS
with/IN
Northern/NN
and/CC
Western/NN
European/NN
ancestry/NN
)/)
,/,
JPT/NN
(/(
Japanese/JJ
in/IN
Tokyo/JJ
,/,
Japan/NNP
)/)
,/,
and/CC
YRI/NN
(/(
Yoruba/NN
in/IN
Ibadan/JJ
,/,
Nigeria/NNP
)/)
./.
====================
We/PRP
focused/VBD
on/IN
the/DT
gene-based/VBN
SNP/NN
associations/NNS
in/IN
the/DT
three/CD
ethnicities/NNS
,/,
because/IN
ethnicity/NN
is/VBZ
a/DT
highly/RB
heritable/JJ
polygenic/JJ
quantitative/JJ
trait/NN
of/IN
biomedical/JJ
importance/NN
./.
====================
Ethnicity-specific/JJ
SNPs/NNS
were/VBD
obtained/VBN
by/IN
eliminating/VBG
common/JJ
SNPs/NNS
./.
====================
Enrichment/JJ
analysis/NN
for/IN
SNP-based/JJ
gene/NN
set/NN
====================
Ethnicity-specific/JJ
HapMap/NN
SNPs/NNS
were/VBD
mapped/VBN
to/TO
genes/NNS
from/IN
UCSC/NN
RefGene/NN
(/(
http/NN
:/:
//genome.ucsc.edu/FW
;/:
ver/RB
./.
====================
hg18/CD
)/)
[/(
12/CD
]/)
./.
====================
For/IN
the/DT
mapped/VBN
genes/NNS
,/,
gene/NN
set/NN
enrichment/JJ
analysis/NN
(/(
GSEA/NN
)/)
was/VBD
performed/VBN
using/VBG
the/DT
Database/NN
for/IN
Annotation/NN
,/,
Visualization/NN
,/,
and/CC
Integrated/JJ
Discovery/NN
(/(
DAVID/NN
ver/RB
./.
====================
6.7/CD
)/)
[/(
13/CD
]/)
with/IN
Gene/NN
Ontology/NN
(/(
GO/NN
)/)
terms/NNS
,/,
including/VBG
biological/JJ
process/NN
(/(
BP/NN
)/)
,/,
cellular/JJ
component/NN
(/(
CC/NN
)/)
,/,
and/CC
molecular/JJ
function/NN
(/(
MF/NN
)/)
./.
====================
The/DT
p-values/NNS
were/VBD
calculated/VBN
for/IN
the/DT
probability/NN
of/IN
getting/VBG
a/DT
set/NN
of/IN
genes/NNS
within/IN
a/DT
given/VBN
GO/NN
group/NN
./.
====================
Semantic/JJ
modeling/VBG
====================
To/TO
look/VB
for/IN
diverse/JJ
interactions/NNS
of/IN
ethnicity-specific/JJ
SNPs/NNS
,/,
we/PRP
constructed/VBD
a/DT
semantic/JJ
model/NN
using/VBG
BioXM/NN
[/(
7/CD
]/)
,/,
which/WDT
efficiently/RB
manages/VBZ
knowledge/NN
,/,
such/JJ
as/IN
complex/NN
scientific/JJ
research/NN
data/NNS
./.
====================
The/DT
model/NN
provides/VBZ
semantic/JJ
networks/NNS
with/IN
useful/JJ
relationship/NN
information/NN
between/IN
participating/VBG
entities/VBZ
./.
====================
Our/PRP$
semantic/JJ
model/NN
consists/VBZ
of/IN
seven/CD
entities/VBZ
,/,
including/VBG
``/RB
Gene/NN
[/(
14/CD
]/)
,/,
''/NNP
``/RB
Pathway/NN
[/(
14/CD
]/)
,/,
''/NNP
``/RB
Disease/NN
[/(
14/CD
]/)
,/,
''/NNP
``/RB
Chemical/JJ
[/(
14/CD
]/)
,/,
''/NNP
``/RB
Drug/NN
[/(
15/CD
]/)
,/,
''/NNP
``/RB
SNP/NN
[/(
12/CD
]/)
,/,
''/NNP
and/CC
``/RB
ClinicalTrials/NNS
(/(
http/RB
:/:
//www.clinicaltrials.gov/DT
)/)
''/RB
,/,
and/CC
10/CD
relations/NNS
,/,
including/VBG
``/RB
Pathway-Gene/NN
,/,
''/NNP
``/RB
Disease-Pathway/NN
,/,
''/NNP
``/RB
Disease-Chemical/JJ
,/,
''/NNP
``/RB
Gene-Disease/NNP
,/,
''/NNP
``/RB
Gene-Chemical/JJ
,/,
''/NNP
``/RB
SNP-Gene/NN
,/,
''/NNP
``/RB
Chemical-Pathway/NNP
,/,
''/NNP
``/RB
Chemical-Drug/NNP
,/,
''/NNP
``/RB
ClinicalTrials-Disease/NN
,/,
''/NNP
and/CC
``/RB
Drug-ClinicalTrials/NNS
./.
''/RB
====================
Conversion/NN
of/IN
all/DT
data/NNS
to/TO
entity/NN
input/NN
format/IN
was/VBD
parsed/VBN
using/VBG
Python/JJ
./.
====================
Discovery/RB
of/IN
ethnicity-specific/JJ
SNPs/NNS
====================
We/PRP
identified/VBD
ethnicity-specific/JJ
SNPs/NNS
by/IN
eliminating/VBG
common/JJ
SNPs/NNS
from/IN
HapMap/NN
samples/NNS
and/CC
mapped/VBD
the/DT
SNP/NN
positions/NNS
to/TO
the/DT
UCSC/NN
RefGene/NN
lists/NNS
./.
====================
22/CD
,/,
25/CD
,/,
three/CD
332/CD
genes/NNS
were/VBD
identified/VBN
in/IN
the/DT
CEU/NN
,/,
in/IN
the/DT
JPT/NN
individuals/NNS
,/,
and/CC
in/IN
the/DT
YRI/NN
individuals/NNS
,/,
respectively/RB
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Comparison/NN
of/IN
the/DT
three/CD
sets/NNS
showed/VBD
that/IN
YRI/NN
individuals/NNS
had/VBD
a/DT
biased/JJ
order/NN
of/IN
SNP-based/JJ
genes/NNS
./.
====================
This/DT
result/NN
was/VBD
a/DT
consensus/NN
among/IN
previous/JJ
evolutionary/JJ
findings/NNS
./.
====================
CEU/NN
and/CC
JPT/NN
belong/IN
to/TO
the/DT
same/JJ
cluster/NN
,/,
together/RB
with/IN
Amerindians/NNS
and/CC
Australopapuan/JJ
,/,
while/IN
YRI/NN
belongs/VBZ
to/TO
a/DT
separate/JJ
cluster/NN
showing/VBG
the/DT
first/JJ
split/NN
between/IN
Africans/NNS
and/CC
non-Africans/JJ
[/(
16/CD
,/,
17/CD
]/)
./.
====================
African/JJ
populations/NNS
subdivided/VBD
from/IN
other/JJ
sub-Saharan/JJ
African/JJ
populations/NNS
,/,
and/CC
a/DT
small/JJ
subset/NN
of/IN
this/DT
population/NN
migrated/VBD
out/RP
of/IN
Africa/JJ
in/IN
the/DT
past/NN
100,000/CD
years/NNS
./.
====================
African/JJ
and/CC
non-African/JJ
populations/NNS
divided/VBN
in/IN
the/DT
past/NN
40,000/CD
years/NNS
./.
====================
Phylogenetic/JJ
analysis/NN
of/IN
Y/NN
chromosomal/JJ
haplotypes/NNS
,/,
mtDNA/JJ
,/,
and/CC
autosomes/VBZ
are/VBP
indicative/JJ
of/IN
the/DT
longest/JJS
history/JJ
of/IN
population/NN
subdivision/NN
in/IN
Africa/JJ
./.
====================
Africans/NNS
are/VBP
the/DT
most/JJS
ancestral/JJ
population/NN
in/IN
human/JJ
and/CC
have/VBP
fewer/JJR
sites/NNS
in/IN
linkage/NN
disequilibrium/NN
,/,
compared/VBN
with/IN
non-African/JJ
populations/NNS
[/(
18/CD
]/)
./.
====================
To/TO
explore/VB
the/DT
meaningful/JJ
biological/JJ
information/NN
of/IN
structural/JJ
variations/NNS
,/,
we/PRP
performed/VBD
GSEA/NN
for/IN
the/DT
SNP-based/JJ
genes/NNS
using/VBG
GO/NN
categories/NNS
(/(
BP/NN
,/,
CC/NN
,/,
and/CC
MF/NN
)/)
in/IN
the/DT
DAVID/NN
tool/NN
./.
====================
The/DT
significantly/RB
categorized/VBD
functions/NNS
(/(
p/NN
</JJR
0.01/CD
)/)
of/IN
SNP-based/JJ
genes/NNS
for/IN
YRI/NN
are/VBP
shown/VBN
as/IN
pie/RB
charts/NNS
in/IN
Fig/NN
./.
====================
2/CD
,/,
but/CC
none/NN
was/VBD
significantly/RB
enriched/JJ
for/IN
CEU/NN
and/CC
JPT/NN
./.
====================
Six/CD
groups/NNS
of/IN
BP/NN
and/CC
four/CD
groups/NNS
of/IN
MF/NN
had/VBD
significant/JJ
enrichment/JJ
score/RB
ranges/VBZ
of/IN
1.67-4.85/CD
and/CC
7.16E-04-0.002/CD
,/,
respectively/RB
./.
====================
The/DT
top/NN
pie/VBP
chart/NN
in/IN
BP/NN
presents/VBZ
G-protein-coupled/JJ
receptor/NN
protein/NN
signaling/NN
pathway/NN
,/,
including/VBG
chemotaxis/NN
,/,
and/CC
defense/NN
response/NN
to/TO
bacterium/NN
(/(
Fig/NN
./.
====================
2A/NN
)/)
./.
====================
In/IN
the/DT
enriched/JJ
region/NN
,/,
8/CD
%/NN
of/IN
BP/NN
was/VBD
chemotaxis/NN
(/(
GO/NN
:/:
0006935/CD
)/)
with/IN
an/DT
enrichment/JJ
score/RB
of/IN
3.88/CD
./.
====================
Chemotaxis/NN
contributes/VBZ
to/TO
enhancement/NN
of/IN
disease/NN
aggressiveness/NN
in/IN
African-Americans/NNS
[/(
19/CD
]/)
./.
====================
The/DT
MFs/NNS
that/DT
were/VBD
significantly/RB
enriched/JJ
were/VBD
G-protein-coupled/JJ
receptor/NN
activity/NN
and/CC
binding/NN
,/,
olfactory/JJ
receptor/NN
activity/NN
,/,
and/CC
transmembrane/JJ
receptor/NN
activity/NN
(/(
Fig/NN
./.
====================
2B/NN
)/)
./.
====================
Enriched/VBN
functions/NNS
in/IN
cellular/JJ
components/NNS
were/VBD
keratin/NN
filament/JJ
(/(
GO:0045095/NN
)/)
with/IN
an/DT
enrichment/JJ
score/RB
of/IN
5.86/CD
,/,
which/WDT
contained/VBD
the/DT
KRTAP/NN
gene/NN
family/NN
(/(
KRTAP12-3/NN
,/,
KRTAP4-11/NN
,/,
KRT14/NN
,/,
KRTAP4-4/NN
,/,
KRTAP9-8/NN
,/,
KRTAP10-7/NN
,/,
KRTAP10-8/NN
)/)
./.
====================
KRTAP/NN
genes/NNS
are/VBP
up-regulated/VBN
in/IN
white/JJ
hair/NN
than/IN
in/IN
black/JJ
hair/NN
by/IN
a/DT
microarray/NN
analysis/NN
./.
====================
Immunoreactivity/NN
for/IN
KRTP/NN
genes/NNS
in/IN
white/JJ
hair/NN
follicles/NNS
was/VBD
increased/VBN
compared/VBN
with/IN
black/JJ
hair/NN
./.
====================
Therefore/RB
Choi/NN
et/FW
al/JJ
./.
====================
[/(
20/CD
]/)
suggested/VBD
that/IN
greying/VBG
hair/NN
,/,
a/DT
sign/JJ
of/IN
aging/NN
,/,
is/VBZ
associated/VBN
with/IN
hair/NN
growth/NN
rate/NN
./.
====================
Semantic/JJ
modeling/VBG
for/IN
ethnicity-specific/JJ
SNPs/NNS
====================
Semantic/JJ
modeling/VBG
is/VBZ
an/DT
emerging/VBG
method/NN
for/IN
comprehensively/RB
understanding/NN
complicated/VBN
BPs/NNS
and/CC
spacious/JJ
networks/NNS
[/(
7/CD
]/)
./.
====================
The/DT
continuous/JJ
production/NN
of/IN
increasingly/RB
large-scale/JJ
data/NNS
in/IN
biology/NN
needs/VBZ
better/RBR
visualization/NN
of/IN
complex/NN
and/CC
huge/JJ
biological/JJ
data/NNS
./.
====================
We/PRP
constructed/VBD
a/DT
semantic/JJ
network/NN
model/NN
in/IN
order/NN
to/TO
analyze/VB
biologically/RB
functional/JJ
implications/NNS
for/IN
ethnicity-specific/JJ
SNPs/NNS
./.
====================
Overall/RB
,/,
network/RB
entities/VBZ
were/VBD
used/VBN
,/,
such/JJ
as/IN
``/RB
Gene/NNP
''/RB
(/(
records/RB
,/,
46,354/RB
)/)
,/,
``/RB
Pathway/NNP
''/RB
(/(
records/RB
,/,
362/RB
)/)
,/,
``/RB
Disease/RB
''/RB
(/(
records/RB
,/,
9,647/RB
)/)
,/,
``/RB
Chemical/JJ
''/RB
(/(
records/RB
,/,
153,021/RB
)/)
,/,
``/RB
Drug/NNP
''/RB
(/(
records/RB
,/,
6,712/RB
)/)
,/,
``/RB
ClinicalTrials/NNS
''/RB
(/(
records/RB
,/,
1,273/RB
)/)
,/,
and/CC
``/RB
SNP/NN
''/RB
(/(
records/RB
,/,
379/RB
)/)
,/,
and/CC
pairwise/RB
relationships/RB
between/IN
entity-entity/RB
were/VBD
curated/VBN
as/IN
``/RB
Gene-Pathway/NNP
''/RB
(/(
records/RB
,/,
46,354/RB
)/)
,/,
``/RB
Gene-Disease/NNP
''/RB
(/(
records/RB
,/,
18,391,755/CD
)/)
,/,
``/RB
Gene-Chemical/JJ
''/RB
(/(
records/RB
,/,
308,405/RB
)/)
,/,
``/RB
Disease-Chemical/JJ
''/RB
(/(
records/RB
,/,
401,145/RB
)/)
,/,
``/RB
Disease-Pathway/RB
''/RB
(/(
records/RB
,/,
43,139/CD
)/)
,/,
``/RB
Chemical-Pathway/NNP
''/RB
(/(
records/RB
,/,
196,073/RB
)/)
,/,
``/RB
Chemical-Drug/NNP
''/RB
(/(
records/RB
,/,
1,702/RB
)/)
,/,
``/RB
SNP-Gene/JJ
''/RB
(/(
records/RB
,/,
379/RB
)/)
,/,
``/RB
ClinicalTrials-Drug/NNP
''/RB
(/(
records/RB
,/,
1,419/RB
)/)
,/,
and/CC
``/RB
ClinicalTrials-Disease/NNP
''/RB
(/(
records/RB
,/,
1,210/RB
)/)
./.
====================
Entities/NNS
,/,
including/VBG
``/NN
Pathway/NN
,/,
''/NNP
``/CD
Chemical/JJ
,/,
''/NNP
and/CC
``/FW
Disease/NN
,/,
''/NNP
were/VBD
collected/VBN
from/IN
the/DT
Comparative/JJ
Toxicogenomics/NNS
Database/NN
(/(
CTD/NN
)/)
[/(
14/CD
,/,
21/CD
]/)
,/,
which/WDT
is/VBZ
a/DT
public/JJ
database/NN
to/TO
promote/VB
the/DT
understanding/NN
of/IN
the/DT
interaction/NN
of/IN
genes/NNS
,/,
chemical/JJ
compounds/NNS
,/,
and/CC
disease/NN
networks/NNS
in/IN
human/JJ
health/NN
./.
====================
Drugs/NNS
were/VBD
mapped/VBN
from/IN
DrugBank/NN
[/(
15/CD
,/,
22/CD
]/)
,/,
which/WDT
provides/VBZ
detailed/JJ
drug/NN
action/NN
information/NN
./.
====================
We/PRP
linked/VBD
a/DT
novel/JJ
relationship/NN
for/IN
``/NN
Chemical-Drug/NN
''/CD
and/CC
``/NN
Gene-SNP/NN
''/CD
by/IN
curating/VBG
the/DT
relationship/NN
of/IN
entities/VBZ
using/VBG
Python/JJ
ver/RB
./.
====================
2.6/CD
,/,
and/CC
the/DT
remaining/VBG
relations/NNS
were/VBD
collected/VBN
from/IN
the/DT
CTD/NN
./.
====================
Fig/NN
./.
====================
3/CD
shows/VBZ
that/IN
semantic/JJ
modeling/VBG
of/IN
ethnicity-specific/JJ
SNPs/NNS
is/VBZ
dynamic/JJ
and/CC
flexible/JJ
./.
====================
Hierarchy/RB
structure/NN
is/VBZ
where/WRB
the/DT
parent/JJ
can/MD
have/VB
one/CD
child/JJ
,/,
while/IN
in/IN
Directed/JJ
Acyclic/JJ
Graph/NN
(/(
DAG/NN
)/)
networks/NNS
,/,
like/IN
BioXM/NN
,/,
the/DT
parent/JJ
can/MD
have/VB
more/RBR
than/IN
one/CD
child/JJ
./.
====================
For/IN
example/NN
,/,
Gene/NN
A/NN
is/VBZ
associated/VBN
with/IN
Chemical/JJ
B/NN
or/CC
Pathway/NN
C./FW
Also/RB
,/,
Gene/NN
A/NN
is/VBZ
associated/VBN
with/IN
Drug/NN
C/NN
,/,
because/IN
Gene/NN
A/NN
is/VBZ
a/DT
curated/JJ
interaction/NN
with/IN
Disease/NN
B/NN
,/,
and/CC
Disease/NN
B/NN
is/VBZ
a/DT
curated/JJ
association/NN
with/IN
Drug/NN
C/NN
./.
====================
Ethnicity-specific/JJ
SNPs/NNS
reveals/VBZ
association/NN
with/IN
3/CD
diseases/NNS
and/CC
1/CD
drug/NN
====================
Diseases/NNS
and/CC
drugs/NNS
are/VBP
very/RB
clinically/RB
important/JJ
for/IN
understanding/NN
ethnic/JJ
disparities/NNS
./.
====================
Many/JJ
diseases/NNS
and/CC
drugs/NNS
have/VBP
been/VBN
reported/VBN
to/TO
be/VB
involved/VBN
in/IN
ethnic/JJ
disparities/NNS
,/,
disease/NN
susceptibility/NN
,/,
drug/NN
response/NN
,/,
and/CC
disposition/NN
[/(
23/CD
,/,
24/CD
,/,
25/CD
]/)
./.
====================
We/PRP
curated/VBD
``/CD
SNP-Gene-Disease-Chemical-Drug/NN
''/CD
interactions/NNS
in/IN
the/DT
semantic/JJ
networks/NNS
for/IN
ethnicity-specific/JJ
SNPs/NNS
./.
====================
Using/VBG
these/DT
semantic/JJ
``/CD
Gene-Disease/NN
''/CD
networks/NNS
,/,
we/PRP
analyzed/VBD
the/DT
functional/JJ
implications/NNS
of/IN
ethnic/JJ
variants/NNS
./.
====================
There/EX
were/VBD
123/CD
diseases/NNS
associated/VBN
with/IN
ethnicity-specific/JJ
SNPs/NNS
in/IN
common/JJ
populations/NNS
,/,
3/CD
CEU-specific/JJ
,/,
and/CC
46/CD
YRI-specific/JJ
,/,
but/CC
JPT/NN
had/VBD
no/DT
specified/VBN
disparity/NN
between/IN
different/JJ
ethnic/JJ
populations/NNS
(/(
Supplementary/JJ
Fig/NN
./.
====================
1A/NN
)/)
./.
====================
Three/CD
diseases/NNS
associated/VBN
with/IN
CEU-specific/JJ
SNPs/NNS
were/VBD
shown/VBN
as/IN
phantom/RB
limb/NN
(/(
MESH/NN
:/:
D010591/CD
)/)
,/,
trochlear/JJ
nerve/NN
diseases/NNS
(/(
MESH/NN
:/:
D020432/CD
)/)
,/,
and/CC
vulvitis/NN
(/(
MESH/NN
:/:
D014847/CD
)/)
,/,
while/IN
diseases/NNS
associated/VBN
with/IN
YRI-specific/JJ
SNPs/NNS
were/VBD
observed/VBN
,/,
such/JJ
as/IN
acquired/VBN
immune/JJ
deficiency/NN
syndrome/NN
(/(
AIDS/NN
)/)
-associated/JJ
nephropathy/NN
(/(
AIDSAN/NN
)/)
,/,
hypertension/NN
,/,
primary/JJ
amyloidosis/NN
,/,
and/CC
pelvic/JJ
infection/NN
./.
====================
AIDSAN/NN
(/(
MESH/NN
:/:
D016263/CD
)/)
rates/NNS
are/VBP
higher/JJR
in/IN
African-Americans/NNS
than/IN
whites/NNS
./.
====================
Although/IN
the/DT
mortality/NN
and/CC
morbidity/NN
from/IN
AIDS/NN
infection/NN
are/VBP
reduced/VBN
,/,
AIDSAN/NN
remains/VBZ
a/DT
major/JJ
complication/NN
of/IN
AIDS/NN
infection/NN
(/(
http/NN
:/:
//statgen.ncsu.edu//JJ
)/)
./.
====================
Hypertension/NN
(/(
MESH/NN
:/:
C537095/CD
)/)
is/VBZ
a/DT
disease/NN
threatening/VBG
the/DT
public/JJ
health/NN
in/IN
sub-Saharan/JJ
Africa/NNP
./.
====================
In/IN
some/DT
areas/NNS
,/,
blacks/NNS
exhibit/VBP
higher/JJR
rates/NNS
of/IN
hypertension/NN
than/IN
whites/NNS
./.
====================
Increased/VBN
salt/NN
intake/NN
and/CC
obesity/NN
are/VBP
the/DT
leading/VBG
causes/VBZ
of/IN
the/DT
prevalence/NN
of/IN
hypertension/NN
in/IN
Africa/JJ
[/(
26/CD
]/)
./.
====================
Pelvic/JJ
infection/NN
(/(
MESH/NN
:/:
D034161/CD
)/)
is/VBZ
a/DT
kind/JJ
of/IN
inflammatory/JJ
disease/NN
that/DT
blacks/NNS
are/VBP
more/RBR
prone/NN
to/TO
take/VB
than/IN
other/JJ
ethnic/JJ
groups/NNS
[/(
27/CD
]/)
./.
====================
By/IN
applying/VBG
the/DT
``/NN
SNP-Gene-Disease-Chemical-Drug/NN
''/CD
model/NN
,/,
2/CD
and/CC
14/CD
drugs/NNS
were/VBD
revealed/VBN
with/IN
CEU-specific/JJ
and/CC
YRI-specific/JJ
groups/NNS
,/,
but/CC
JPT-specific/JJ
drugs/NNS
had/VBD
no/DT
results/NNS
(/(
Fig/NN
./.
====================
4/CD
,/,
Supplementary/JJ
Fig/NN
./.
====================
1B/NN
)/)
./.
====================
One/CD
drug/NN
(/(
methylphenidate/NN
,/,
DB00422/NN
)/)
was/VBD
reported/VBN
to/TO
have/VB
ethnic/JJ
disparities/NNS
in/IN
previously/RB
drug/NN
studies/NNS
./.
====================
The/DT
mean/JJ
dose/NN
of/IN
methylphenidate/JJ
is/VBZ
about/RB
1.5/CD
times/NNS
higher/JJR
in/IN
African-Americans/NNS
than/IN
whites/NNS
[/(
28/CD
]/)
,/,
and/CC
its/PRP$
use/NN
is/VBZ
steadily/RB
increasing/VBG
in/IN
South/NN
Africa/NNP
[/(
29/CD
]/)
./.
====================
Ethnicity-specific/JJ
associations/NNS
with/IN
5/CD
pathways/NNS
====================
Analysis/NN
using/VBG
the/DT
semantic/JJ
model/NN
for/IN
ethnicity-specific/JJ
SNPs/NNS
identified/VBN
5/CD
,/,
7/CD
,/,
and/CC
100/CD
CEU-specific/JJ
,/,
JPT-specific/JJ
,/,
and/CC
YRI-specific/JJ
biochemical/JJ
pathways/NNS
,/,
respectively/RB
./.
====================
In/IN
hemostasis/NN
(/(
REACT:604/NN
)/)
,/,
associated/VBN
with/IN
cardiovascular/JJ
diseases/NNS
,/,
plasminogen/NN
activator/NN
inhibitor-1/NN
activity/NN
levels/NNS
of/IN
Africans/NNS
are/VBP
lower/JJR
compared/VBN
to/TO
Caucasians/NNS
./.
====================
These/DT
negative/JJ
effects/NNS
can/MD
be/VB
seen/VBN
already/RB
at/IN
a/DT
young/JJ
age/NN
./.
====================
If/IN
addressed/VBN
in/IN
early/JJ
life/NN
,/,
it/PRP
is/VBZ
possibly/RB
adjustable/JJ
through/IN
behavior/NN
and/CC
optimal/JJ
dietary/JJ
changes/NNS
[/(
30/CD
]/)
./.
====================
Systemic/JJ
lupus/NN
activity/NN
measure/VB
(/(
SLAM/NN
;/:
KEGG:05322/NN
)/)
scores/VBZ
were/VBD
higher/JJR
in/IN
African-Americans/NNS
(/(
mean/NN
=/JJ
12.6/CD
)/)
and/CC
Hispanics/NNS
(/(
11.0/CD
)/)
than/IN
in/IN
Caucasians/NNS
(/(
8.5/CD
)/)
./.
====================
It/PRP
caused/VBD
lack/NN
of/IN
health/NN
insurance/NN
,/,
onset/NN
of/IN
abrupt/VBP
disease/NN
,/,
presence/NN
of/IN
anti-Ro/JJ
(/(
SSA/NN
)/)
antibody/NN
,/,
absence/NN
of/IN
HLA-DRB/NN
,/,
high/JJ
levels/NNS
of/IN
helplessness/NN
,/,
and/CC
abnormal/JJ
illness/NN
behaviors/NNS
./.
====================
Caucasians/NNS
lived/JJ
under/IN
less/RBR
crowded/JJ
conditions/NNS
,/,
had/VBD
less/RBR
abnormal/JJ
illness/NN
behaviors/NNS
,/,
and/CC
had/VBD
more/RBR
education/NN
./.
====================
The/DT
results/NNS
of/IN
the/DT
regression/NN
analyses/NNS
were/VBD
showed/VBD
significant/JJ
association/NN
between/IN
higher/JJR
SLAM/NN
scores/VBZ
and/CC
higher/JJR
helplessness/RB
,/,
absence/NN
of/IN
HLA-DRB1*0301/NN
,/,
and/CC
presence/NN
of/IN
HLA-DRB*0201/NN
(/(
p/NN
</JJR
0.01/CD
)/)
[/(
31/CD
]/)
./.
====================
Prostate/NN
cancer/NN
(/(
KEGG:05215/NN
)/)
is/VBZ
a/DT
diagnosed/JJ
male/JJ
reproductive/JJ
system/NN
cancer/NN
./.
====================
Incidence/RB
of/IN
prostate/NN
cancer/NN
in/IN
African-American/JJ
men/NNS
is/VBZ
higher/JJR
than/IN
in/IN
European/JJ
men/NNS
(/(
1.6/CD
times/NNS
)/)
./.
====================
Amundadottir/PRP$
et/FW
al/JJ
./.
====================
[/(
32/CD
]/)
identified/VBD
that/WDT
the/DT
chromosomal/JJ
8q24/NN
region/NN
is/VBZ
most/RBS
frequently/RB
gained/VBN
in/IN
prostate/NN
cancers/NNS
,/,
and/CC
this/DT
gained/VBN
region/NN
has/VBZ
been/VBN
correlated/VBN
with/IN
aggressive/JJ
tumors/NNS
[/(
33/CD
]/)
./.
====================
Estimated/JJ
population/NN
attributable/JJ
risk/NN
is/VBZ
greater/JJR
in/IN
Africans/NNS
than/IN
in/IN
European/JJ
populations/NNS
./.
====================
Hepatitis/NN
C/NN
virus/NN
(/(
HCV/NN
;/:
KEGG:05160/CD
)/)
is/VBZ
a/DT
major/JJ
cause/VBP
of/IN
chronic/JJ
liver/NN
disease/NN
in/IN
humans/NNS
./.
====================
Rates/NNS
of/IN
HCV/NN
prevalence/NN
in/IN
sub-Saharan/JJ
Africa/NNP
are/VBP
the/DT
highest/JJS
in/IN
central/JJ
Africa/NNP
(/(
3.0/CD
%/NN
)/)
compared/VBD
with/IN
the/DT
median/JJ
(/(
2.2/CD
%/NN
)/)
./.
====================
Conjeevaram/NN
et/FW
al/JJ
./.
====================
[/(
34/CD
]/)
showed/VBD
that/IN
African-Americans/NNS
with/IN
chronic/JJ
HCV/NN
have/VBP
lower/JJR
response/NN
to/TO
interferon-based/JJ
antiviral/JJ
therapy/NN
than/IN
Caucasian/JJ
Americans/NNS
[/(
35/CD
]/)
./.
====================
Rheumatoid/JJ
arthritis/NN
(/(
RA/NN
;/:
KEGG:05323/NN
)/)
is/VBZ
an/DT
autoimmune/JJ
disease/NN
and/CC
may/MD
affect/VB
many/JJ
organs/NNS
./.
====================
The/DT
RA/NN
prevalence/NN
in/IN
urban/JJ
South/NN
Africans/NNS
is/VBZ
similar/JJ
in/IN
Caucasians/NNS
[/(
36/CD
]/)
./.
====================
In/IN
the/DT
current/JJ
study/NN
,/,
the/DT
pathways/NNS
shared/VBN
between/IN
all/DT
populations/NNS
were/VBD
signal/JJ
transduction/NN
(/(
REACT:111102/NN
)/)
,/,
olfactory/JJ
transduction/NN
(/(
KEGG:04740/CD
)/)
,/,
and/CC
metabolic/JJ
pathways/NNS
(/(
KEGG:01100/NN
)/)
./.
====================
These/DT
pathways/NNS
were/VBD
common/JJ
disease-pathway/NN
interactions/NNS
in/IN
previous/JJ
research/NN
./.
====================
Although/IN
ethnicity-specific/JJ
genes/NNS
are/VBP
identified/VBN
in/IN
each/DT
population/NN
,/,
it/PRP
is/VBZ
generally/RB
observed/VBN
that/IN
genes/NNS
that/WDT
are/VBP
associated/VBN
with/IN
a/DT
trait/JJ
or/CC
disease/NN
can/MD
converge/VB
to/TO
the/DT
same/JJ
pathway/NN
[/(
37/CD
]/)
./.
====================
Those/DT
genes/NNS
are/VBP
also/RB
supposed/VBD
to/TO
converge/VB
to/TO
common/JJ
pathways/NNS
shared/VBN
between/IN
all/DT
populations/NNS
./.
====================
Therefore/RB
,/,
a/DT
pathway-based/JJ
approach/NN
allows/VBZ
us/PRP
to/TO
systematically/RB
evaluate/VBP
multiple/JJ
polymorphic/JJ
genes/NNS
from/IN
different/JJ
populations/NNS
with/IN
respect/NN
to/TO
pathways/NNS
as/IN
a/DT
biological/JJ
unit/NN
[/(
38/CD
]/)
./.
====================
Moreover/RB
,/,
the/DT
pathway-based/JJ
approach/NN
has/VBZ
more/RBR
capability/NN
to/TO
detect/VB
rare/JJ
genetic/JJ
variants/NNS
with/IN
a/DT
small/JJ
effect/NN
that/IN
do/VBP
not/RB
survive/VB
at/IN
the/DT
stringent/JJ
significance/NN
level/NN
[/(
39/CD
]/)
./.
====================
We/PRP
identified/VBD
ethnicity-specific/JJ
SNPs/NNS
from/IN
HapMap/NN
data/NNS
and/CC
constructed/VBD
a/DT
semantic/JJ
network/NN
model/NN
for/IN
the/DT
HapMap/NN
SNP/NN
dataset/NN
./.
====================
Functional/JJ
studies/NNS
were/VBD
analyzed/VBN
with/IN
genebased/VBN
ethnicity-specific/JJ
SNPs/NNS
./.
====================
Our/PRP$
semantic/JJ
network/NN
model/NN
showed/VBD
robust/JJ
interactions/NNS
between/IN
ethnic-specific/JJ
SNPs/NNS
and/CC
public/JJ
data/NNS
./.
====================
However/RB
,/,
this/DT
model/NN
is/VBZ
still/RB
in/IN
the/DT
early/JJ
stage/NN
,/,
and/CC
greater/JJR
data/NNS
connection/NN
and/CC
development/NN
of/IN
more/RBR
flexible/JJ
algorithms/NNS
are/VBP
required/VBN
./.
====================
We/PRP
expect/VBP
that/DT
our/PRP$
semantic/JJ
network/NN
model/NN
is/VBZ
useful/JJ
for/IN
ethnicity-specific/JJ
SNPs/NNS
,/,
and/CC
our/PRP$
findings/NNS
will/MD
provide/VB
prioritization/NN
of/IN
ethnicity-specific/JJ
gene-based/VBN
SNP/NN
candidates/NNS
./.
====================
